Placebo-controlled trial showing subcutaneous semaglutide treatment resulted in a higher percentage of NASH resolution in NASH patients than placebo
This is because the Congressional Budget Office (CBO), Congresss official scorekeeper for proposed legislation, would incorporate the cost of coverage for these other uses into its baseline estimates for Medicare spending, which means that the incremental cost of changing the law to allow Medicare coverage for anti-obesity drugs would be lower than it would be without FDAs approval of these drugs for other uses
The data is consistent across trials: tirzepatide 15mg produces ~6 percentage points more weight loss than semaglutide 2.4mg, and even tirzepatide's lowest dose (5mg) matches semaglutide's maximum
Second, the FDA has identified instances of compounded semaglutide products that do not contain the correct amount of active ingredient, contain impurities, or are not sterile when they should be
Allowing you to control your hunger , not your hunger controlling you Your Weight Loss Success story starts today
This ensures your treatment plan, including dosing schedules and injection guidance, is tailored specifically to you
